Menu
  • Join
  • Login
  • Contact
 

Search abstracts


Development of formulations of sorafenib tosylate for improved biopharmaceutical potential

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: SHARMA, Teenu (Panjab University, University institute of Pharmaceutical sciences)
  • Co-author(s): Teenu Sharma: University institute of Pharmaceutical sciences, Panjab University, Chandigarh, India
    Atul Jain: UGC-CoE ANNN, Panjab University, Chandigarh, India
    O P Katare: University institute of Pharmaceutical sciences, Panjab University, Chandigarh, India
    Bhupinder Singh: UGC-CoE ANNN, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh, India
  • Abstract:

    Background

    Sorafenib tosylate, BCS class II anticancer drug, exhibits low oral bioavailability (8%) ostensibly owing to poor aqueous solubility, high first-pass effect and P-gp efflux. 

    Methods

    The patient-centric quality target product profile (QTPP) and critical quality attributes (CQAs) were earmarked. Ishikawa Fish-bone diagram was constructed

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses